



**Sarra El-Abed**

**Kontakt**

Sarra El-Abed

## Publikationen (8)

Fernandez-Martinez A, Rediti M, Tang G, Pascual T, Hoadley K, Venet D, Rashid N, Spears P, Islam N, El-Abed S, Bliss J, Lambertini M, Di Cosimo S, Huober J, Goerlitz D, Hu R, Lucas P, Swain S, Sotiriou C, Perou C, Carey L. Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials. *JAMA Oncol* 2024

Di Cosimo S, Ciniselli C, Pizzamiglio S, Cappelletti V, Silvestri M, El-Abed S, Izquierdo M, Bajji M, Nuciforo P, Huober J, Cameron D, Chia S, Gomez H, Iorio M, Vingiani A, Pruneri G, Verderio P. End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO. *Front Oncol* 2023; 12:1028825.

Nuciforo P, Townend J, Piccart M, Fielding S, Gkolfi P, El-Abed S, de Azambuja E, Werutsky G, Bliss J, Moebus V, Colleoni M, Aspitia A, Gomez H, Gombos A, Coccia-Portugal M, Tseng L, Kunz G, Lerzo G, Sohn J, Semiglazov V, Saura C, Kroep J, Ferro A, Cameron D, Gelber R, Huober J, Di Cosimo S. Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer. *Eur J Cancer* 2022; 181:92-101.

Ligorio F, Huober J, Moscetti L, Janni W, Coccia-Portugal M, Corsetto P, Belfiore A, Lorenzini D, Daidone M, Vingiani A, Gianni L, Pupa S, Bianchini G, Pruneri G, Nuciforo P, de Azambuja E, Izquierdo M, Di Cosimo S, Verderio P, Ciniselli C, Pizzamiglio S, Castagnoli L, Dugo M, Galbardi B, Salgado R, Loi S, Michiels S, Triulzi T, Tagliabue E, El-Abed S, Vernieri C. Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab. *J Natl Cancer Inst* 2022

van Rees D, Saura C, Di Cosimo S, Huober J, Roylance R, Kim S, Kuijpers T, van Bruggen R, K van den Berg T, Guillaume S, Izquierdo M, El-Abed S, Bouti P, Klein B, Verkuijlen P, van Houdt M, Schornagel K, Tool A, Venet D, Sotiriou C, Matlung H. Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex. *J Immunother Cancer* 2022; 10

Pizzamiglio S, Huober J, Ellard S, Rimm D, Gombos A, Daidone M, Verderio P, Tagliabue E, Di Cosimo S, Nuciforo P, Bajji M, Cosentino G, Ciniselli C, De Cecco L, Cataldo A, Plantamura I, Triulzi T, El-Abed S, Wang Y, Iorio M. What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study. *Cancer Med* 2021; 11:332-339.

Vathiotis I, Kim S, Harbeck N, Gomez H, Shafi S, Syrigos K, Fountzilas G, Sotiriou C, Pusztai L, Warren S, Di Cosimo S, Huober J, Nuciforo P, Moutafi M, Divakar P, Aung T, Qing T, Fernandez A, Yaghoobi V, El-Abed S, Wang Y, Guillaume S, Rimm D. Alpha-smooth muscle actin expression in the stroma predicts resistance to trastuzumab in patients with early-stage HER2-positive breast cancer. *Clin Cancer Res* 2021

Venet D, Gomez H, Semiglazov V, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart-Gebhart M, Loi S, Rothé F, Saura C, Wang Y, Rediti M, Maetens M, Fumagalli D, Brown D, Majjaj S, Salgado R, Pusztai L, Harbeck N, El-Abed S, Sotiriou C. Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical trial. *Clin Cancer Res* 2021

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)